Darolutamide (Nubeqa) is accepted for use within NHS Scotland

Approved for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. In a phase III study in men with high risk nmCRPC, darolutamide was superior to placebo for metastasis-free survival.

Source:

Scottish Medicines Consortium